Camp4 Therapeutics annual ebitda
2022
2023
2024
2025
Camp4 Therapeutics EBITDA Growth & History (CAMP)
Camp4 Therapeutics's calculated EBITDA was −$50.9M for fiscal 2025.
View full Camp4 Therapeutics company overviewCamp4 Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$50.9M | $476,000 | — |
| 2024 | 2024-12-31 | −$51.4M | −$1.2M | — |
| 2023 | 2023-12-31 | −$50.2M | −$6.1M | — |
| 2022 | 2022-12-31 | −$44.1M | — | — |
Camp4 Therapeutics quarterly ebitda
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$12.9M | −$252,000 | — |
| Q1 2026 | 2026-03-31 | −$12.6M | $128,000 | — |
| Q4 2025 | 2025-12-31 | −$12.4M | $1.2M | — |
| Q3 2025 | 2025-09-30 | −$13.3M | −$135,000 | — |
| Q2 2025 | 2025-06-30 | −$12.6M | −$366,000 | — |
| Q1 2025 | 2025-03-31 | −$12.7M | −$240,000 | — |
| Q4 2024 | 2024-12-31 | −$13.6M | — | — |
| Q3 2024 | 2024-09-30 | −$13.1M | −$1.2M | — |
| Q2 2024 | 2024-06-30 | −$12.3M | — | — |
| Q1 2024 | 2024-03-31 | −$12.4M | — | — |
| Q3 2023 | 2023-09-30 | −$11.9M | — | — |
Camp4 Therapeutics ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Camp4 Therapeutics's ebitda decreased from −$44.1M to −$50.9M, a change of −$6.8M. The latest reported quarter, Q2 2026, shows −$12.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Camp4 Therapeutics source filings ↗Community posts
CAMP4 receives UK authorization for its first SYNGAP1 clinical study
CAMP4 Therapeutics ($CAMP) received UK authorization to include sites in its global Phase 1/2 study of CMP002, an investigational treatment for SYNGAP1-related disorder. The decision follows earlier clearances in Australia and Argentina, wh ...